Announcement of the list of construction units for the centralized production base of batch of drugs in short supply

[industry trends of China Pharmaceutical network] on January 28, 2019, the Ministry of industry and information technology issued the notice of four departments on publishing the list of construction units of the centralized production base of batch of small drug varieties (short drugs) In recent years, the shortage of life-saving drugs such as protamine has aroused great concern of the society In 2017, 139 varieties were included in the list of drugs in short supply In 2018, the health and health commission established and improved the monitoring context and hierarchical response system for the shortage of drugs, identified more than 500 monitoring outposts for the shortage of drugs, sorted out the list of 139 clinically vulnerable drugs, and most of them have resumed production and supply The relevant person in charge pointed out that the reasons for the shortage of drugs involve various links of drug research and development, production, circulation and use All over the country, the price is too low in the centralized purchase of drugs, which leads to the fact that although the enterprise wins the bid, the profit is not much and it is difficult to sustain However, the hospital has not completely transferred to the public welfare orientation, resulting in the lack of motivation for low-cost drug procurement Market speculation and monopoly will also cause artificial shortage   In order to ensure the normal supply of drugs, China has issued a series of policies, including improving the monitoring and early warning system of drugs in short supply, establishing the management system of the list of drugs in short supply at the national and provincial levels, strengthening the tracking and monitoring of the supply of APIs in order to respond in a timely manner, strengthening the fight against violations of laws and regulations, and promoting state-owned enterprises to play a better role in the supply of drugs in short supply To promote the solution of the supply of difficult and short drugs This notice is aimed at the production link of drugs It is to carry out the construction of the centralized production base of drugs in short supply, which will break the bottleneck for the lack of power in the production of drugs in short supply in China, further guarantee the supply of drugs in short supply in China, and provide guarantee for the quality, safety and drug demand of the people The notice shows that according to the notice on organizing the construction of the centralized production base of small drug varieties (short drugs), the Ministry of industry and information technology, the health and Health Commission, the development and Reform Commission and the drug administration have identified the construction unit of the centralized production base of small drug varieties (short drugs), which is now announced According to the notice of relevant matters, the construction unit of the centralized production base of small drug (short drug) shall complete the construction task of the centralized production base of small drug (short drug) according to the construction cycle and responsibility objective requirements, so as to ensure the stable production and supply of small drug (short drug) Relevant departments in Beijing, Shanghai, Sichuan and other provinces (cities) should implement the responsibility of territorial supervision, strengthen the management and guidance of the construction unit, urge the enterprises to ensure the quality and safety of drugs, and improve the ability to guarantee the supply of drugs in short supply Strengthen consultation and linkage, and timely coordinate to solve the difficulties and problems encountered by the construction unit The relevant departments of each province (city) should actively support the local enterprises to carry out the construction of the centralized production base of small drug (short drug), focus on the cultivation of enterprises with better conditions, and prepare for the next batch of selection and identification According to the list of construction units for the centralized production base of batch of small products and varieties of drugs (drugs in short supply), a consortium led by Shanghai Pharmaceutical Group Co., Ltd is organized and implemented by Shangyao Xinyi Pharmaceutical Co., Ltd and 23 enterprises The consortium led by China Pharmaceutical Group Co., Ltd is organized and implemented by Shanghai Modern Pharmaceutical Co., Ltd and China Biotechnology Co., Ltd The consortium led by Chengdu Beite Pharmaceutical Co., Ltd is organized and implemented by nine enterprises including Chengdu Beite Pharmaceutical Co., Ltd and Chongqing Yaoyou Pharmaceutical Co., Ltd.